Nouscom
OverviewSuggest Edit
Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.
| Type | Private | |
| Founded | 2015 | |
| HQ | Basel, CH | Map |
| Website | nouscom.com |
Recent NewsAll News
- Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer
- Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability
- Nouscom Strengthens Its Management Team
- Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
Latest Updates
| Employees (est.) (Jan 2021) | 27 | |
| Cybersecurity rating | B | More |
Key People/Management at Nouscom
Riccardo Cortese
Co-Founder
Marina Udier
Chief Executive Officer
Stefano Colloca
Chief Technical Officer and Co-Founder
Tiffany Muller
VP Finance
Alfredo Nicosia
Co-Founder, Advisor
Cinzia Traboni
Senior Director of Regulatory Affairs and Co-Founder
Nouscom Office Locations
Nouscom has offices in Basel and Roma
Basel, CH (HQ)
18 Bäumleingasse
Roma, IT
100 Via di Castel Romano
Nouscom Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Nouscom total Funding | $62.6 m |
Nouscom latest funding size | $49 m |
Time since last funding | 3 years ago |
Nouscom investors | Versant Ventures, 5AM Ventures, Abingworth, LSP BioVentures, LSP |
Nouscom's latest funding round in November 2017 was reported to be $49 m. In total, Nouscom has raised $62.6 m
Nouscom Cybersecurity Score
Nouscom Online and Social Media Presence
Nouscom's Trends
Nouscom News and Updates
December 11, 2020
Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer
BASEL, Switzerland, Dec. 11, 2020 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed Göran Ando, MD as the new Chairman of its Board of Directors. Nouscom also appointed...
July 22, 2020
Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability
BASEL, Switzerland, July 22, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the publication of new research describing the cutting-edge science and rationale for the design of NOUS-209 and...
February 26, 2020
Nouscom Strengthens Its Management Team
BASEL, Switzerland, Feb. 26, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that it has appointed Marina Udier, PhD, as Chief Executive Officer (CEO) and Patricia Delaite, MD, as Chief Medical...
December 09, 2019
Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
BASEL, Switzerland, Dec. 9, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, NOUS-209. In this...
June 03, 2019
Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors
BASEL, Switzerland, June 3, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug (IND) application for the first clinical trial of its lead candidate NOUS-209 has...
November 05, 2018
Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director
BASEL, Switzerland, November 5, 2018 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed John F. McDonald as an...
Nouscom Blogs
December 08, 2020
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and crosspresentation of locally expressed endogenous tumor antigens…
December 01, 2020
New viral vectors for infectious diseases and cancer
ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into the current approaches of viral vectored genetic vaccines. In recent years, key improvements to the vacci…
February 26, 2020
Nouscom Strengthens its Management Team
Marina Udier, PhD, appointed as Chief Executive Officer and Patricia Delaite, MD, appointed as Chief Medical Officer BASEL, Switzerland – 26. February 2020: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that it has appointed…
December 09, 2019
Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
BASEL, Switzerland – 9 December 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, NOUS-209. In this first-in-human trial NOUS…
November 01, 2019
Nouscom will join & present at the SITC 2019
Nouscom will join & present at the SITC 2019 from November 6-10.
L'articolo Nouscom will join & present at the SITC 2019 proviene da Nouscom.
October 07, 2019
Nouscom is presenting at the TMB & Neoantigen Congress
Nouscom will present at the TMB & Neoantigen Congress from October 10-11, 2019 in London.
L'articolo Nouscom is presenting at the TMB & Neoantigen Congress proviene da Nouscom.
Nouscom Frequently Asked Questions
When was Nouscom founded?
Nouscom was founded in 2015.
Who are Nouscom key executives?
Nouscom's key executives are Riccardo Cortese, Marina Udier and Stefano Colloca.
How many employees does Nouscom have?
Nouscom has 27 employees.
Who are Nouscom competitors?
Competitors of Nouscom include Stealth BioTherapeutics, Fauna Bio and Affinia Therapeutics.
Where is Nouscom headquarters?
Nouscom headquarters is located at 18 Bäumleingasse, Basel.
Where are Nouscom offices?
Nouscom has offices in Basel and Roma.
How many offices does Nouscom have?
Nouscom has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies